Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

CStone Pharmaceuticals Announces China's NMPA has Accepted its New Drug Application for anti-PD-L1 Monoclonal Antibody Sugemalimab in First-Line Advanced NSCLC

prnasiaNovember 12, 2020

Tag: CStone Pharmaceuticals , NMPA , NSCLC , Sugemalimab , CS1001-302

PharmaSources Customer Service